NCT07866261|Not Yet Recruiting
Loading search results
Sponsor study identifier
interventional
54
0 countries
N/A
Study Start
October 10, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
October 10, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This randomized controlled trial aims to compare the efficacy and safety of transconjunctival versus transcutaneous perilevator betamethasone injection in reducing upper eyelid retraction in patients with thyroid eye disease.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 4, 2026
Actual (reported)October 8, 2026
Actual (reported)October 10, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 10, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
March 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Change in Margin Reflex Distance 1
Mean change in Margin Reflex Distance 1 (MRD1) in millimeters from baseline to 3 months after the first injection.
At 3 months
Proportion of eyes with effective response
At 3 months
Mean number of injections required
At 12 months
Proportion of eyes with intraocular pressure elevation
At 12 months
Change in Graefe sign
At 3 months
Perilevator betamethasone injection delivered via the transconjunctival (subconjunctival/retro-septal) approach.
Perilevator betamethasone injection delivered via the transcutaneous (percutaneous para-levator) approach.
Betamethasone suspension 1 mL injected into the perilevator space.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Abdelnasser m Awad, prof
Ophthalmology Department, Assiut University Hospitals
Sarah H Alataar, Prof
Ophthalmology Department,Assiut University Hospitals
First Submitted
October 4, 2026
First Posted
October 8, 2026
Study Start
October 10, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy
Contact the study team to confirm eligibility.
Primary Completion
October 10, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 8, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: